A similar role in chemotherapy resistance has been reported for LAT1 in patients with metastatic or recurrent pancreatic ductal adenocarcinoma after surgical resection, with all patients with high LAT1 expression being identified as non-responders to fluorouracil (5-FU) and gemcitabine [149]. Here, SLC7A5 is linked to pancreatic ductal adenocarcinoma.